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Association of predicted 10 years 
cardiovascular mortality risk with duration 
of HIV infection and antiretroviral therapy 
among HIV-infected individuals in Durban, 
South Africa
Olamide O. Todowede1*, Benn Sartorius1,2,4, Nombulelo Magula3 and Aletta E. Schutte5,6
Abstract 
Background: South Africa has the largest population of human immunodeiciency virus (HIV) infected patients 
on antiretroviral therapy (ART) realising the beneits of increased life expectancy. However, this population may be 
susceptible to cardiovascular disease (CVD) development, due to the chronic consequences of a lifestyle-related com-
bination of risk factors, HIV infection and ART. We predicted a 10-year cardiovascular mortality risk in an HIV-infected 
population on long-term ART, based on their observed metabolic risk factor proile.
Methods: We extracted data from hospital medical charts for 384 randomly selected HIV-infected patients aged 
≥ 30 years. We deined metabolic syndrome (MetS) subcomponents using the International Diabetes Federation dei-
nition. A validated non-laboratory-based model for predicting a 10-year CVD mortality risk was applied and catego-
rised into ive levels, with the thresholds ranging from very low-risk (< 5%) to very high-risk scores (> 30%).
Results: Among the 384 patients, with a mean (± standard deviation) age of 42.90 ± 8.20 years, the proportion of 
patients that were overweight/obese was 53.3%, where 50.9% had low high-density lipoprotein (HDL) cholesterol 
and 21 (17.5%) had metabolic syndrome. A total of 144 patients with complete data allowed a deinitive prediction 
of a 10-year CVD mortality risk. 52% (95% CI 44–60) of the patients were stratiied to very low risk (< 5%) compared to 
8% (95% CI 4–13) that were at a very high risk (> 30%) of 10-year CVD mortality. The CVD risk grows with increasing 
age (years), 57.82 ± 6.27 among very high risk and 37.52 ± 4.50; p < 0.001 in very low risk patients. Adjusting for age 
and analysing CVD risk mortality as a continuous risk score, increasing duration of HIV infection (p = 0.002) and ART 
(p = 0.007) were signiicantly associated with increased predicted 10 year CVD mortality risk. However, there was no 
association between these factors and categorised CVD mortality risk as per recommended scoring thresholds.
Conclusions: Approximately 1 in 10 HIV-infected patients is at very high risk of predicted 10-year CVD mortality 
in our study population. Like uninfected individuals, our study found increased age as a major predictor of 10-year 
mortality risk and high prevalence of metabolic syndrome. Additional CVD mortality risk due to the duration of HIV 
infection and ART was seen in our population, further studies in larger and more representative study samples are 
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Background
he introduction of antiretroviral therapy (ART) in the 
management of human immunodeiciency virus (HIV) 
infection has resulted in increased life expectancy of 
infected patients, altering HIV pathogenesis from an 
acute to a chronic disease [1]. Despite this recogniz-
able success of ART, there are still challenges faced by 
people living with HIV, such as increased prevalence of 
metabolic and cardiovascular abnormalities such as lipid 
abnormalities, diabetes and hypertension [2, 3]. hese 
conditions can occur individually, but more often occur 
as a cluster of cardiovascular disease (CVD) risk factors, 
known as metabolic syndrome (MetS), which increases 
the risk of CVD above what is anticipated for any indi-
vidual risk factor [4–8].
HIV-infected individuals have a twofold higher risk of 
CVD morbidity and mortality compared to their unin-
fected counterparts [9–11]. he main factors leading to 
these events include HIV infection, inlammation and 
autoimmune response, ART and the high cardiovascu-
lar risk proile of HIV-infected patients [12–14]. he 
mechanisms of these factors to induce cardiovascular 
risk are not clear, although an interplay between factors 
and their complexities have been suggested [15]. CVD 
risk varies by demographic and clinical factors of the HIV 
infected populations, for instance some studies showed 
that severe co-infection increased the risk of CVD in 
their population while ART adherence and high CD4 
count reduce the risk [16, 17]. Other studies indicated the 
role of protease inhibitors and abacavir, HIV associated 
inlammation and immune activation to accentuate the 
risk of CVD among HIV infected populations [18, 19]. 
Moreover, lifestyle-related CVD risk factors such as diet, 
obesity, alcohol intake and smoking, common among 
the general population, further compound the suscepti-
bility of people living with HIV to increased metabolic 
disturbance [14, 20]. Corroborating evidence indicates 
increased CVD mortality among people with individual 
and clustered risk factors (MetS), especially in men and 
older populations [21, 22].
A systematic review and meta-analysis conducted 
among HIV-infected populations in sub-Saharan African 
(SSA) countries indicated a strong association between 
the use of ART and CVD mortality risk [23]. Similarly, 
another meta-analysis suggested HIV infection is a con-
sistent risk factor for CVD outcomes, though this varied 
by geographical location [12]. he association of ART 
and HIV infection with increased CVD risk has been 
mostly documented in high-income countries (HIC). 
However, there is paucity of data reporting this in HIV-
hyperendemic setting and in many low-and-middle-
income countries (LMICs) [24]. A study in Uganda 
estimated the 10-year absolute risk of cardiovascular dis-
eases (CVD) among HIV infected populations who were 
on ART [25]. he association between HIV and CVD risk 
could be modiied in LMIC settings due to other con-
tributors occurring in many of them, such as rapid nutri-
tional, early onset of HIV infection and ART uptake and 
epidemiological transitions.
herefore, understanding the potential CVD burden in 
a hyperendemic HIV context is important to inform rou-
tine clinical care, as well as for its prevention and man-
agement by clinicians [26, 27]. We therefore assessed the 
burden of metabolic risk factors and predicted 10-year 
CVD mortality risk in an HIV-infected population on 
long-term ART. We further evaluated the relationship 
between duration of HIV infection and ART use and the 
predicted 10-year CVD mortality.
Methods
Aim of the study
he aim was to assess the burden of metabolic risk fac-
tors and predict 10-year CVD mortality risk in an HIV-
infected population on long-term ART. We showed the 
relationship between the duration of HIV infection and 
ART on cardiovascular mortality risk.
Study sample
his study is a cross-sectional study (medical chart 
review) of HIV-infected patients attending Addington 
Hospital’s antiretroviral clinic an urban setting in Durban, 
South Africa, from 2004 to 2017. We extracted data from 
384 patient iles, selected using a simple random sam-
pling approach from a total population of ~ 3800 unique 
patient iles available over this period. A patient was 
deemed eligible if they attended at least one follow-up 
visit after ART initiation and was aged ≥ 30 years. hese 
criteria are supported by the South African guidelines 
for the management of HIV/AIDS, which indicate that 
HIV-infected patients should have at least two follow-
up visits per year [28]. A non-laboratory-based approach 
was employed for estimating 10-year CVD mortality risk 
among our HIV-infected cohort, this was implored as a 
result of missing total cholesterol measurement from 
encouraged. It recommends an urgent need for early planning, prevention and management of metabolic risk factors 
in HIV populations, at the point of ART initiation.
Keywords: HIV, Cardiovascular risk score, Metabolic syndrome, Antiretroviral therapy
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most patients charts at the facility. Evidence suggests that 
the use of body mass index (BMI) instead of total cho-
lesterol levels gives a similar or better prediction of CVD 
risk estimation, especially in low resource settings with 
limited access to laboratory testing [29, 30]. he model 
incorporates the following risk factors in the prediction: 
age, BMI, current smoker, history and or presence of dia-
betes, history of blood pressure treatment and systolic 
blood pressure [30]. he predicted CVD mortality risk 
was analyzed as a continuous and categorical variable, 
and the categorized variant was based on the following 
conventional thresholds: ‘very low’ (< 5%), ‘low’ (5–9.9%), 
‘moderate’ (10–19.9%), ‘high’ (20–29.9%), and ‘very 
high’ (> 30%) [31, 32]. Ethical approval for this study was 
obtained from the Biomedical Research Ethics Commit-
tee (BREC), reference number (BE437/16), at the Univer-
sity of KwaZulu-Natal.
Data collection
Data were extracted from patient charts using a stand-
ardized instrument that was pilot tested. he following 
information was extracted: demographic—age, sex, race, 
place of residence; risk factors—smoking, adherence to 
ART treatment, past and present tuberculosis diagnosis, 
blood pressure readings; and anthropometric—baseline 
BMI, height and weight. We also extracted blood pro-
ile results for fasting plasma glucose and lipid labora-
tory data (serum HDL cholesterol level, total cholesterol, 
serum LDL cholesterol, triglycerides); dates of HIV-
infection conirmation and ART initiation; and records 
of present treatment of hypertension and type 2 diabetes. 
Other comorbidities (known and recorded presence of 
non-communicable diseases in the patient’s chart) were 
extracted when available. If available, data were tracked 
for all patients at baseline and for at least one or more 
subsequent follow-up visit at the time of this chart audit. 
Information on the current and past ART regimen per 
patient was also extracted. Data captured on the same 
date as ART initiation are classiied as the patient’s base-
line record in this study and ordered sequentially for 
subsequent visits based on the date of presentation. Data 
were double-entered into an Epi Info 7 database with 
built-in validation checks.
Metabolic risk factor classiication
We used the cutof for raised fasting plasma glucose of 
≥ 100  mg/dL or 5.6  mmol/L or reported diagnosis and 
treatment for type 2 diabetes. Similarly, high blood pres-
sure was referred to as systolic pressure of ≥ 130 mmHg 
and/or a diastolic pressure of ≥ 85  mmHg or reported 
diagnosis and treatment for hypertension. Other risk 
factors were deined as raised triglycerides > 150  mg/
dL (1.7 mmol/L), reduced HDL cholesterol (< 40 mg/dL 
(1.03 mmol/L) in men and < 50 mg/dL (1.29 mmol/L) in 
women) or speciic treatment for this lipid abnormal-
ity. hese deinitions are incorporated using the Inter-
national Diabetes Federation (IDF) deinitions for MetS 
[33]. Body mass index (BMI) was classiied into the fol-
lowing three categories: normal < 25  kg/m2, overweight 
25–29.9 kg/m2, and obese ≥ 30 kg/m2.
Data analysis
Data were analysed using STATA version 13.0 [34]. he 
mean and standard deviation (SD) or median (25th–
75th percentiles) were calculated for continuous vari-
ables. Diference between means was assessed using the 
Student’s  t-test or Wilcoxon rank-sum test (also known 
as the Mann-Whitney U test), if the normality assump-
tion was not upheld. he Pearson Chi square (χ2) test was 
used to measure the strength of linear relationship or the 
Fisher’s exact test (if fewer than 5 expected observations 
in all cells in the contingency table) was used to test the 
association between categorical variables. he correla-
tion between the predicted CVD risks was assessed using 
the Spearman correlation; whereas the diferences in the 
correlation coeicients across the various settings were 
tested using the Steiger’s Z test. All statistical tests were 
assessed at a 5% signiicance level.
Results
Characteristics of the study participants
A total of 384 randomly selected patient charts were 
included in this study, with the socio-demographic 
description of individual risk factors presented in Table 1. 
However, only 144 patients had complete chart records 
on all the risk factors required for the assessment of their 
CVD mortality risk (Fig. 1). Of the 384 patient charts, we 
observed a mean age of 42.9 (SD8.2) years, 256 (66.3%) 
were female, and 353 (91.7%) were Black African. he age 
distribution of the patients are 30–34 (16.15%), 35–39 
(27.08%), 40–44 (21.88%), 45–49 (14.58%), 50–59 (4.17%), 
60–64 (3.13%) and 1.30% were aged 65 years and above. 
he mean duration of participants conirmed to be HIV 
infected was 6.3 ± 4 years. Overall, 201 (52.1%) and 107 
(27.7%) participants had, or were presently taking, the 
irst- and second-line ART, respectively, with only two 
patients on third-line therapy. However, 76 (19.7%) had 
a missing record of the past or present class of regimen. 
Tuberculosis infection was the highest comorbidity, with 
157 (45%) patients having been previously infected. he 
most common noncommunicable disease (NCD) comor-
bidities among participants were 30 (7.5%) with hyper-
tension, 22 (5.7%) with renal impairment, 14 (3.6%) with 
asthma and there were no cases of lipodystrophy. Over-
all, 270 patients had a useable baseline BMI measure-
ment, with a mean BMI of 26.5 ± 6.8 kg/m2. Women [54 
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(29.7%)] were signiicantly more overweight than men [9 
(8%); p < 0.001] and 61 (33.5%) women versus 21 (23.6%) 
men [p < 0.001] were obese.
Prevalence of metabolic syndrome and metabolic risk 
factors
he prevalence of individual metabolic risk factors of 
the study participants at baseline (i.e. treatment ini-
tiation) is shown in Table  2. Of the 270 patients with a 
valid BMI classiication, 144 (53.2%) were overweight 
or obese. Among the 206 patients with a blood pres-
sure measurement taken at baseline, most were classi-
ied in the normal blood pressure range, at 163 (79.1%). 
Similarly, among the 246 patients with blood glucose 
records and the 111 patients with triglyceride records, 
74% were classiied in the normal blood glucose range 
and 66.7% had normal triglyceride levels respectively. An 
almost equal proportion of the patients with HDL cho-
lesterol records presented with both low HDL cholesterol 
and a normal range of the good cholesterol [57 (50.9%) 
vs 55 (49.1%); p < 0.010]. Among the 384 participants, 
there were 165 that could be reliably classiied using the 
IDF MetS deinitions alluded to previously, due to miss-
ing subcomponent data. Among these 165 participants, 
21 (17.5%) were classiied as having MetS, with higher 
prevalence in females [19 (90.5%)] than males [2 (9.5%)]. 
here was no statistically signiicant diference in the age 
distribution when stratiied by metabolic syndrome clas-
siication (p = 0.102), (Additional ile 1: Table S3).
Estimated 10‑year cardiovascular mortality risk
A total of 144 patients had a complete dataset that was 
modeled for predicting 10-year cardiovascular mortality 
risk; of these, 107 were females. In this study, the largest 
proportion of the population belonged in the very low 
risk group (< 5%) at 52.1% [(75/144, 0.52 (95% CI 0.44–
0.60)]. his was 57.0% among females and 37.8% among 
males (p = 0.136). A signiicant decrease in the propor-
tion of patients is observed as the prediction moves from 
very low risk (< 5%) to very high risk (> 30%)—Fig.  2. 
Approximately 6% [(9/144, 0.06 (95% CI 0.03–0.12)] 
of this study population were classiied in the low risk 
(20–29.9%) 10-year CVD mortality risk category. Simi-
larly, about 8% [(0.08 (95% CI 0.04–0.13)] of the patients 
were at a greater than 30% 10-year risk of CVD mortality. 
However, the stratiication of the proportion of our study 
sample, by the CVD mortality risk scores, was statisti-
cally insigniicant (Fig. 2 p = 0.136). here was a signii-
cant positive association between presence of Mets and 
Table 1 Characteristics of the study participants (N = 384)
i: Wilcoxon rank-sum test; **: signiicant at 1% level; *: signiicant at 5% level; #: signiicant at 10% level
Characteristics N All patients 
(mean ± SD)
Men (mean ± SD) Women (mean ± SD) P‑value i
Age (years) 384 42.82 (8.3) 43.26 (8.2) 42.54 (8.4) 0.121
HIV infection duration (years) 220 6.33 (3.9) 5.78 (4.0) 6.72 (3.9) 0.047*
ART duration (years) 383 6.18 (3.43) 5.82 (3.5) 6.39 (3.4) 0.094#
CD4 cell counts (cells/µL) 364 407.5 (254.6) 347.9 (207.2) 437.9 (271.0) 0.005**
Height (metres) 270 162.7 (9.2) 169.1 (9.6) 159.5 (7.2) < 0.001**
Weight (Kg) 377 70.8 (17.0) 69.1 (14.0) 71.7 (18.3) 0.324
BMI (kg/m2) 270 26.5 (6.8) 23.7 (5.7) 27.9 (6.8) < 0.001**
Systolic blood pressure (mmHg) 206 120.3 (19.8) 129.7 (25.7) 118.2 (17.3) 0.052#
Diastolic blood pressure (mmHg) 207 80.6 (55.0) 79.8 (18.1) 80.9 (63.5) 0.191
Blood glucose (mmol/L) 246 5.6 (2.4) 5.8 (2.4) 5.5 (2.5) 0.012*
Triglycerides (mmol/L) 111 1.6 (1.1) 1.9 (1.4) 1.5 (0.9) 0.096#
HDL cholesterol (mmol/L) 112 1.3 (0.4) 1.2 (0.3) 1.3 (0.4) 0.194
Abstracted Data
N= 384 
Age
n=384
Systolic blood
pressure
n=206 
Type 2
diabetes
n=246 
Body mass
index
n=270 
Data available 
for all risk 
factors
N= 144
Fig. 1 Flow chart of study participants with updated records
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10-year cardiovascular mortality risk category, with 5 
(33.33%), p = 0.002 of patients at very high risk had MetS, 
(Additional ile 1: Table S4).
Duration of HIV infection, antiretroviral therapy 
and cardiovascular mortality risk
Table  3 displays the estimation of the ive categories of 
non-laboratory-based CVD mortality risk scores com-
pared by age, duration of years of HIV infection, and 
ART use. We observed an increase in the mean age of our 
sample from very low-risk (37.52 ± 4.50 years), moderate-
risk (48.05 ± 5.64 years), to the very high-risk score band 
(57.82 ± 6.27  years). he median duration of HIV-infec-
tion conirmation among patients who were at a very 
low CVD mortality risk was 6.64 (3.63–9.86) years, while 
those at moderate-risk was 6.91 (5.11–8.02) years and the 
very high-risk was 7.20 (4.49–11.05) years. Nonetheless, 
a higher proportion of patients who had been on ART for 
longer than 7.96 ± 4.38 years were in the high-risk score 
band, compared to the very low-risk 6.52 ± 3.47  years’ 
band for CVD mortality. his study showed that duration 
of HIV infection and ART didn’t correlate with the pre-
dicted CVD mortality risk categorized thresholds.
However, analysing the predicted 10-year CVD mor-
tality risk as a continuous risk score and adjusting for 
patients’ age, increasing duration of ART (p = 0.007) and 
HIV infection (p = 0.002) were signiicantly associated 
with increased patient’s susceptibility to the risk of CVD 
mortality. (Additional ile 1: Table S1).
The proportion of other related factors with CVD mortality 
risk
A bivariate analysis (Table 4) of our study sample could 
not suggest if race was associated with high or very high 
risk of CVD mortality among our population, as the pro-
portion of Black Africans to other races in our study is 
not comparable. Patients who had changed from the 
irst-line and were presently on second-line ART regimen 
[8/70 (11.43%)], were more likely to be classiied as very 
high risk than those on irst-line treatment [3/73 (4.11%)], 
but this was not statistically signiicant (p = 0.211). 
Among those with previous tuberculosis infection, there 
appeared to be a lower likelihood of being at a very high 
risk of CVD compared to those without previous tuber-
culosis infection [(3/70 (4.29%) versus 8/72 (11.11%), 
p = 0.063].
Table 2 Prevalence of individual risk factors for cardiovascular disease
Characteristic Range Overall
(384)
n (%)
Male (128)
n (%)
Female (256)
n (%)
p‑value
BMI (Kg/m2) Underweight 12 (4.4) 7 (7.9) 5 (2.7) < 0.001
Normal 115 (42.4) 53 (59.6) 62 (34.1)
Overweight 75 (27.7) 21 (23.6) 54 (29.7)
Obese 69 (25.5) 8 (9) 61 (33.5)
Blood pressure (mmHg) < 130/80 163 (79.1) 42 (75) 121 (80.7) 0.373
≥ 130/80 43 (20.9) 14 (25) 29 (19.3)
Plasma glucose
(mmol/L)
< 5.6 182 (74) 54 (69.2) 128 (76.2) 0.247
≥ 5.6 64 (26) 24 (30.8) 40 (23.8)
Triglycerides
(mmol/L)
< 1.7 74 (66.7) 19 (63.3) 55 (67.9) 0.650
≥ 1.7 37 (33.3) 11 (36.7) 26 (32.1)
Low HDL
(mmol/L)
Male < 1.03,
Female < 1.29
55 (49.1) 9 (29) 46 (56.8) < 0.01
Male ≥ 1.03,
Female > 1.29
57 (50.9) 22 (71) 35 (43.2)
Fig. 2 Predicted 10-year CVD death risk stratiied by sex
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Analysing 10-year cardiovascular mortality risk as a 
linear variable using a continuous regression formula-
tion (Bivariate and multivariable adjusted), age (p < 0.001) 
remained independently associated with 10  year pre-
dicted CVD mortality risk. he analyses also suggest an 
association between African ethnicity (p < 0.001), hav-
ing previous TB infection (p = 0.014) and being female 
(p < 0.001) and increased CVD mortality risk.
here was no diference in baseline CD4 when com-
paring individuals with MetS to those without (median 
baseline CD4 of 452.5 [IQR: 332–667] versus 390 [IQR: 
210–589], p-value = 0.285). Furthermore, median base-
line CD4 ranged from 363 (IQR: 227–525) among those 
classiied with < 5% 10-year cardiovascular mortality risk 
to 389.5 (IQR: 194–508) among those with 30+% 10-year 
cardiovascular mortality risk (p-value = 0.484).
Discussion
HIV-infected and treated patients are susceptible to 
increased CVD risk factors, as well as cardiovascular 
morbidity and mortality outcomes. Although this sus-
ceptibility is associated with traditional risk factors, HIV 
infection, antiretroviral regimen and dynamics that ema-
nate from the infection may also contribute to increased 
cardiovascular risk [35–37]. his present study reports 
the proportion of metabolic syndrome, metabolic risk 
factors and the associations thereof with the duration of 
HIV infection and ART. We also predicted the 10-year 
CVD mortality risk in HIV-infected patients treated for a 
mean duration of 6.18 years.
he study participants are aged 30  years and above, 
with the mean age of 42.90 ± 8.20. Most of the patients 
(45%) have had tuberculosis in the past, which empha-
sizes the epidemic of HIV/TB co-infection in South 
Africa [38]. We realised a signiicantly high prevalence of 
overweight and obesity among our patients. hese were 
more prevalent among the female participants, and con-
irms the epidemic of obesity in our setting [39]. Most of 
our study samples had normal blood pressure (79.1%), 
though this was a baseline record. here is a probability 
of increase blood pressure over time among the popula-
tion that was not monitored, understanding that South 
Africa has high burden of high blood pressure [40]. 
Recent study in South Africa among HIV infected cohort 
showed a high prevalence of hypertension at baseline and 
about 15% increased prevalence at follow -up after ART 
initiation [41]. In Denmark, a low prevalence of hyper-
tension was reported in their population [42]. However, 
Table 3 Relationship between  age, duration of  HIV infection and  antiretroviral therapy (in years) and  cardiovascular 
mortality risk score classiication
i One-way analysis of variance ANOVA with Bonferroni correction for multiple testing
Variables (years) Risk score
< 5.00% 5.00–9.9% 10.00–19.9% 20.00–29.9% > 30.00% P‑valuei
Age
 N 75 26 23 9 11
 Mean (SD) 37.52 (4.50) 44.47 (5.52) 48.05 (5.64) 51.67 (4.36) 57.82 (6.27) Overall: < 0.001
Duration of HIV infection
 N 41 16 12 7 5
 Median (P25–P75) 6.64 (3.63–9.86) 8.11 (4.46–11.07) 6.91 (5.11–8.02) 7.41 (2.20–12.10) 11.51 (7.11–11.69) 0.684
Duration since ART initiation
 N 75 26 23 9 11
 Median (P25–P75) 6.37 (4.44–9.06) 8.26 (4.64–11.01) 6.19 (4.78–7.31) 7.39 (7.11–11.85) 8.09 (6.83–10.55) 0.119
Table 4 Bivariate analysis of factors associated with CVD mortality risk
Ο Fisher’s exact test; * Pearson Chi square (χ2) test, α Coloured and White
Variables Total (N = 144) < 5.00% 5.00–9.90% 10.00–19.90% 20.00–29.90% > 30.00% P value
Black Africans 133 71 (53.38) 24 (18.05) 23 (17.29) 9 (6.77) 6 (4.51) < 0.001Ο
Other  racesα 11 4.0 (36.36) 2 (18.18) – – 5 (45.45)
1st line regimen 73 37 (50.68) 13 (17.81) 16 (21.92) 4 (5.48) 3 (4.11) 0.211*
2nd line regimen 70 37 (52.86) 13 (18.57) 7 (10) 5 (7.14) 8 (11.43)
Previous tuberculosis 70 44 (62.86) 8 (11.43) 11 (15.71) 4 (5.71) 3 (4.29) 0.063Ο
No tuberculosis 72 30 (41.67) 18 (25.00) 11 (15.28) 5 (6.94) 8 (11.11)
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this outcomes depends on ART adherence, type of ART 
use and the study population [41]. Our study found 
an increased prevalence of MetS (17.5%), especially in 
African women and supports the known increased high 
age-standardized CVD mortality rate in South Africa, 
driven by high blood pressure and obesity [43]. Age-
standardized CVD mortality is increasing in sub-Saharan 
Africa countries, though varies by countries and mostly 
driven by growing age and population’s health transi-
tion from communicable to non-communicable diseases 
[44–46]. Obesity and overweight, associated with the 
increasing presence of lipid disorder such as low HDL 
cholesterol and raised triglycerides, is prevalent in HIV-
infected patients [47, 48]. his factors are associated with 
the development of metabolic disorder and CVD out-
comes and this was indicated in our results. Additionally, 
related studies conducted in some Northern American 
and Europe reported that people living with HIV with 
increased age (45–60  years) were more inclined to die 
from CVD compared to the general population [26, 49], 
as our study indicates.
We showed that most of the study samples (52%) 
were at a very low risk of CVD mortality, especially 
women. In Uganda, a large HIV positive cohort popu-
lation study, showed that men were at high 10-year 
risk of acute CVD and ART treated populations were 
more at risk of longer term CVD, as suggested in our 
study [25]. Of our study patients, 8% were shown to be 
at greater than a 30% 10-year risk of CVD mortality, 
similar to what was reported among a general popula-
tion (5.7% and above) with a comparable age range in 
Germany and India [50, 51]. We have shown that there 
is a linear association between older age, patients who 
have been on ART for longer, and are in the high-risk 
score band (7.96 ± 4.38  years) compared to very low 
risk (6.51 ± 3.47  years) for CVD mortality. Predicted 
CVD mortality risk was not associated with the dura-
tion of treatment or HIV infection using the categorized 
threshold scores but was independently associated with 
increased age. Moreover, in a multivariate analysis and 
adjusting for age, duration of HIV infection and ART 
were signiicantly associated with 10  years predicted 
CVD mortality risk. his result emphasizes the addi-
tional efect of HIV related and individual components 
of MetS on the susceptibility to CVD mortality risk, at 
the absence of increased age. HIV infection, immune 
activation and inlammation are related to cardiovas-
cular risk among the population, characterized by the 
complex interaction of systematic factors at all stages 
of HIV-infection progression [13, 16]. Likewise, both 
untreated HIV-infected and treated persons are adversely 
susceptible to CVD outcomes [19]. Nonetheless, stud-
ies have suggested CVD development to be more greatly 
associated with the duration and type of ART regimen 
(speciic classes) than HIV-infection itself [52–55]. A 
recent study strengthens this evidence, reporting a high 
prevalence of metabolic risk factors among infected 
patients who have been on a protease inhibitor regimen, 
with 35% cardiovascular mortality at a 30-day endpoint 
[56, 57]. HIV-infected patients have shown a substantial 
development of CVD and its outcome progression within 
three years of ART initiation [58]. Islam et al. [59] showed 
a yearly increasing CVD risk among treated HIV-infected 
patients, establishing that the duration of ART exposure 
is strongly associated with CVD outcome. Višković et al. 
[13] analyzed the association between the presence of 
CVD biomarkers and related HIV-infected patient char-
acteristics. he results of their study showed a positive 
correlation between the duration of HIV infection and 
ART and the presence of CVD markers, with a median 
of 8 and 6  years respectively [13]. hough in a Danish 
population, ageing, duration of ART initiation and HIV 
infection were not related with the risk of CVD [60]. his 
present study indicates a linear probability of a 10-year 
CVD mortality risk among its patients and the relation-
ship between duration of infection or treatment [61].
Several studies have suggested CVD as an increas-
ing cause of mortality in HIV-infected patients [26, 49]. 
A report shows the existence of a mutual interaction 
between traditional risk factors and HIV related factors 
namely HIV infection and long-term use of ART [15]. 
he traditional factors include high BMI, low HDL, 
which has shown to be prevalent among this study 
participants. American Heart Association recently 
reported that high BMI has shown to be indepen-
dently associated with signiicant higher risk of death 
attributable to CVD [62]. In South Africa, participants 
with mean age 46 years and mostly African men, were 
within moderate to high CVD risk, in the presence of 
increased metabolic factors such as high blood pres-
sure, high blood glucose [63]. Our study relates with 
literature that CVD death among HIV infected popula-
tion has increased over the same period AIDS mortal-
ity decreased, even after matching and controlling for 
CVD known risk factors [64]. A huge reduction of CVD 
mortality is feasible by improving the distribution of 
risk factors in a population, which is applicable in our 
participants [65]. Treated HIV patients are clearly at a 
comparable CVD risk as general population, with the 
strong inluence of aging HIV population. HIV infected 
population study in Brazil showed that HIV speciic 
risk factors were strongly associated with CVD mor-
tality risk than the traditional risk factors as age [66]. 
his variation emphasizes the complex interplay of dif-
ferent sets of risk factors for CVD mortality by popu-
lations [67]. his underlines the emerging need for an 
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enhanced CVD risk-prediction model for HIV-infected 
populations, as a CVD mortality prediction tool has 
been reported to underestimate cardiovascular risk in 
HIV patients [26, 68, 69]. Studies have argued that the 
relationship between risks of CVD in HIV populations 
remains obscure and inconclusive, as the clinical sig-
niicance of an absolute risk of CVD risk remains low in 
the HIV-infected population, speciically with certain 
types of ART [70, 71].
Our study indicated most of the population were at low 
risk of CVD mortality. Noteworthy is the modest popu-
lation size used for the estimation, which might not give 
the true relection of the general population. Our study 
suggests that screening of CVD risk factors (as noted 
by the large number of missing information during the 
patient record review) occurs less frequently in health-
care practice than is recommended [72]. his resulted 
in few patients with complete variables for more precise 
estimation of CVD mortality risk compared to the target 
study sample size initially Our results are of interest and 
importance to public health, while taking our limitations 
into account. We relied on hospital -based patient medi-
cal chart reported diagnoses, though these might not be 
complete and entirely give accurate representation of our 
population, resulting in underestimation. Most of our 
subjects were females and of the African race, our results 
may not be generalizable to other populations. We have 
used cross-sectional data (chart audit) to predict the rela-
tionship between the duration of HIV infection and ART 
on cardiovascular mortality risk, hence causation can-
not be ascertained. We were unable to include an HIV-
uninfected control population from the same region to 
compare the 10-year CVD risk. Moreover, studies among 
the South African general population have reported a 
high prevalence of CVD risk factors, ranging between 
21.8 and 42.6% speciically among females [73–75]. his 
study also acknowledges another limitation in that we 
used the South African national smoking proportion to 
estimate the prevalence of smoking among our present 
population. However, this variable does not contribute 
much weight to our analysis [76]. Our study was not 
able to incorporate cholesterol concentrations as one of 
the variables of the CVD mortality risk estimation; how-
ever, the use of BMI is equally reliable for the prediction 
[32]. Nevertheless, we found a high proportion of meta-
bolic risk factors with the possibility of cardiovascular 
mortality risk in a population of treated and stable HIV-
infected patients. Our study recommends the scaling up 
of the routine monitoring of CVD risk factors during the 
management of HIV infection and treatment. his is sup-
ported by studies that have shown the increased suscepti-
bility of the general population to CVD, including people 
living with HIV [16, 77].
Conclusions
In summary, in a South African population infected 
with HIV for a mean duration of 6 years, we found rela-
tionship between duration of infection and duration of 
ART use with a 10-year predicted CVD mortality risk. 
However, predicted CVD mortality risk was strongly 
associated with age, as would also be expected in an 
uninfected population. Where 1 in 2 participants had 
increased adiposity, only 7% had hypertension. here 
was an implication of increased age, HIV infection and 
ART to the population’s predisposition to a predicted 
10-year cardiovascular mortality risk. his implies 
that treated HIV patients should be as equally consid-
ered for CVD risk management as would be uninfected 
patients. However, modiiable risk factors may also have 
increased their susceptibility, so further studies are 
needed to clarify the risk diferences between the con-
tribution of traditional risk factors and HIV-related fac-
tors. his will assist with planning early prevention and 
management of metabolic risk factors and cardiovascu-
lar disorder outcomes in HIV-infected populations.
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